CXCL-10 |
Monocytes |
Monocytes, macrophages, NK cells, DCs and LT chemotaxis |
Inflammation |
Severe disease [70] |
Interferon-gamma (IFN-Υ) |
NK cells and LT-CD4+ (Th1) |
IL-4 inhibition, Th1 differentiation, increased MHC I and II expression |
Inflammation and anti-viral immune response |
Lung injury [71] |
IL-1β |
Macrophages |
LB proliferation and differentiation, phagocytes stimulation |
Inflammation |
Decreased oxygen saturation, poor outcome [72,73] |
IL-2 |
Activated LT-CD4+, LB and monocytes |
NK and T cell activation and proliferation, B cell activation along with IL-4 |
Inflammation and antigen-specific stimulation |
ICU-hospitalization [35,72] |
IL-4 |
LT-CD4+ (Th2) |
LB differentiation and proliferation, increased expression of MHC-II |
Antigen-specific humoral response |
Mild disease [70] |
IL-6 |
Lymphocytes and monocytes |
Increased acute inflammation-cytokines release, eosinophil chemotaxis |
Immune modulation (pro or anti-inflammatory), antigen-specific response, and anti-viral response |
Decreased oxygen saturation, poor outcome, increased risk of death [73,74] |
IL-8 |
Macrophages |
Neutrophil and granulocytes chemotaxis, phagocytosis stimulation |
Inflammation |
Severe disease, increased risk of death [74,75] |
IL-10 |
LT-CD8+ |
Inhibition of Th1 cytokines, decreased cytolytic response |
Inflammation |
Severe disease and ICU hospitalization [35,75] |
IL-17 |
LT-CD4+ (Th17) |
Neutrophil activation |
Inflammation, mucosal activation, tissue repair |
Decreased oxygen-saturation and lung injury [71,73], mild disease [70] |
Tumor-necrosis factor (TNF)-α |
Macrophages |
Phagocytes chemotaxis and phagocytosis stimulation |
Inflammation |
Severe disease, ICU hospitalization, and increased risk of death [35,74,75] |